Just a moment, the page is loading...
The Supported Studies Programme
For the latest updates on GSK’s response to COVID-19, please click here.

Consumer Health



Timelines





The below areas are of particular interest to the review committee. This was last updated in April 2020.


[Oral Health]
New plaque-reducing or plaque-inhibiting solutions
The build-up of dental plaque is the precursor for several oral diseases, including gum disease. In the early stages, this can lead to soreness, inflammation and bleeding of the gums on brushing. Therefore, we are seeking to develop products that help reverse the early signs of gum disease and prevent it from recurring.
To achieve this, we are seeking opportunities that reduce or inhibit the attachment of plaque to oral surfaces or that break up existing plaque without the need for antimicrobials. Ideally, these ingredients can be incorporated into a mouthwash or toothpaste, but other formats would also be considered.

Gum health
Sodium bicarbonate is an ingredient in various toothpastes to help tackle early-stage gum disease (gingivitis) and maintain healthy gums. However, when present in high concentrations, sodium bicarbonate gives the toothpaste a very strong, salty taste which results in low acceptability by consumers. We are seeking solutions to mask the salty taste in toothpastes with high concentrations of sodium bicarbonate, so that this acceptance barrier is overcome and consumers can benefit from these products.

Enamel health
Teeth are subject to numerous challenges throughout the day from dietary sugars, acids and bacteria. Despite the use of fluoridated toothpaste and mouthwash, all of these factors have contributed to a significant rise in the number of fillings, enamel wear and sensitivity. Therefore, we are seeking solutions that would protect tooth enamel from these challenges and/or repair the damage that has been caused.

Tooth loss
• Replacement options and patient impressions
• Implications and consequences: Function, Oral hygiene, QoL
• Role of dental professionals in managing change/transition for patients facing/ living with tooth loss

Care of appliances as part of daily oral hygiene routine
• Oral hygiene needs of partially dentate patients
• Evidence base for prevention of oral diseases in partially dentate populations
• New/ alternative cleanser technologies for maintenance of fixed and removable appliances and implants

Fit and performance of dental appliances
• Comfort
• Adhesion
• Masticatory function
• Ease of adaptation and patient learnings required
• Patients perceived needs and preferences

Dentine Hypersensitivity
Dentin hypersensitivity is a relatively common condition; it is one of the most commonly encountered clinical problems in dentistry. Dentine hypersensitivity is characterized by tooth pain in response to stimuli such as hot and cold food and can have a marked impact the enjoyment of daily activities and quality of life. However, the condition is manageable, and we continue to seek to develop products that help prevent the pain of dentine hypersensitivity, and explore new understandings on the condition, including impacts on quality of life, objective measures of pain and physiological parameters.

[Pain relief]
GSK scientists research and develop new self-treatment options targeting mild to moderate pain associated to multiple indications. The goal of GSK 's research in pain is to provide treatments and interventions that significantly improve the lives of patients living with a range of painful conditions.

[Respiratory]
• Upper respiratory tract infections
• Allergic and non-allergic rhinitis
• Tobacco addiction & smoking cessation/reduction
• Air pollution

[Skin health]
• Cold sores
• Feet and Nail fungus infections
• Itchy, inflamed and irritated skin

[Digital & Devices]
Digital health can be broadly defined as the use of digital technology, data and the internet to improve either access, efficiency, the consumer/patient experience, or outcomes (or a combination of these) in healthcare.

GSK welcomes research proposals in the field of digital health. We have a broad scope of interest for such proposals and are keen to hear of any which may include studies that:
• Assess the use of apps and other digital technologies to improve health outcomes or the patient/consumer experience in any of the therapy areas in which GSK has a publicly declared interest
• Address the areas of resilience, pain, anxiety, smoking cessation (and other forms of addiction), health-related behaviour change, weight management, wellness, mental health, oral health, allergy, infectious diseases and cold & flu
• Assess the utility of digital therapeutics or platforms in areas of interest, where the therapeutic/platform may be a standalone intervention or an adjunct to a conventional medicine/medical device
• Investigate the potential health benefits of wearable technologies
• Investigate innovative ways to collect real world evidence on healthcare interventions
• Investigate innovative ways to monitor/assess the safety of healthcare interventions
• Investigate consumer, patient, HCP, regulator or policymaker attitudes to, and acceptance of, digital health interventions
• Investigate how digital health interventions may reduce the burden on healthcare systems

Although GSK are more likely to support studies aligned to our current areas of interest for supported studies, we are interested in supporting studies that are innovative and contribute to scientific knowledge relating to a product, a medical condition or advancing a technology.



© 2001-2020 GlaxoSmithKline plc. All rights reserved. Registered in England and Wales No. 3888792.
Registered office: 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom.